Nuvation Bio (NUVB) Hisse Özeti
Klinik aşamada bir biyofarmasötik şirketi olan Nuvation Bio Inc. kanser tedavisi için ürün adayları geliştirmeye odaklanmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 5/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 4/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
Risk kontrollerimizden NUVB için herhangi bir risk tespit edilmedi.
NUVB Community Fair Values
Create NarrativeSee what 37 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Nuvation Bio Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$6.83 |
| 52 Haftanın En Yüksek Seviyesi | US$9.75 |
| 52 Haftanın En Düşük Seviyesi | US$2.68 |
| Beta | 1.52 |
| 1 Aylık Değişim | 6.22% |
| 3 Aylık Değişim | 44.70% |
| 1 Yıllık Değişim | 149.27% |
| 3 Yıllık Değişim | 316.46% |
| 5 Yıllık Değişim | -30.31% |
| Halka arzdan bu yana değişim | -29.59% |
Son Haberler & Güncellemeler
Recent updates
NUVB: Safusidenib Glioma Data Will Drive Future Upside Potential
Analysts have nudged their average price target for Nuvation Bio higher from about $12.33 to roughly $13.11, citing recent safusidenib trial updates, upward revisions to individual targets as high as $21, and an expanded view of the long term glioma treatment opportunity. Analyst Commentary Recent Street research on Nuvation Bio focuses heavily on safusidenib data and how that might translate into future revenue potential and stock valuation.
NUVB: Glioma Data And Lung Cancer Progress Will Shape Future Upside And Risks
Analysts have trimmed their fair value estimate for Nuvation Bio from $8.00 to $7.00 as they factor in a slightly higher discount rate, more moderate projected revenue growth, and updated views on long term profitability and future P/E, while also citing supportive safusidenib data and a revised $19 price target. Analyst Commentary on Nuvation Bio Recent research commentary on Nuvation Bio centers on updated safusidenib data and how that could influence long term valuation, especially in relation to the company’s revised fair value estimate and price target.NUVB: UK Regulatory Progress For Lead Oncology Asset Will Drive Future Upside
Analysts have adjusted their fair value estimate for Nuvation Bio to $12.33 from $10.25, citing updated assumptions on discount rates, future profitability and P/E expectations, alongside recent sector commentary around biotech earnings and capital flows. What’s in the News for Nuvation Bio Nuvation Bio reported that partner Eisai’s Marketing Authorisation Application for taletrectinib in advanced ROS1-positive non small cell lung cancer was validated by the UK Medicines and Healthcare products Regulatory Agency, moving the therapy into formal UK regulatory review (source: company announcement and partner Eisai).
NUVB: Convertible Notes Raise Will Support Advancing Lead Oncology Portfolio
Analysts have lifted their price target on Nuvation Bio from about $16.80 to roughly $19.70, reflecting updated assumptions for revenue growth, profit margins, discount rate and future P/E that they see as better aligned with the company’s current outlook. What’s in the News for Nuvation Bio Nuvation Bio plans to raise up to US$230 million through a convertible senior notes offering maturing in 2032.Nuvation Bio: David Hung's Latest Venture Looks Undervalued At Current Level
Summary I initiate coverage of Nuvation Bio with a Moderate Buy, citing undervaluation based on two value-driving oncology assets. NUVB's fundamentals hinge on Ibtrozi (taletrectinib), a next-gen ROS1 inhibitor now commercial, and safusidenib, a late-stage mutant IDH1 inhibitor. My sum-of-the-parts analysis yields a $5.6/share fair value, with further upside from M&A potential, re-rating anchored on recent M&A activity, and milestone payments. Risks include Ibtrozi's revenue ramp, patent runway, and clinical uncertainty for safusidenib, but a strong balance sheet limits near-term dilution. Read the full article on Seeking AlphaResults: Nuvation Bio Inc. Confounded Analyst Expectations With A Surprise Profit
Investors in Nuvation Bio Inc. ( NYSE:NUVB ) had a good week, as its shares rose 8.1% to close at US$4.81 following the...Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst
Summary Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for NSCLC. The FDA has accepted Nuvation's New Drug Application for the drug, assigning it priority review and a PDUFA date of June 23, 2025. Taletrectinib shows clearly superior clinical data compared to rivals, with a potential market opportunity of ~$3.8bn by its fourth year, despite current market skepticism. Concerns include reliance on Chinese study data and competition from established pharma giants, but Nuvation's cash reserves suggest readiness for a wide-scale launch. Ahead of the PDUFA date, Nuvation presents a speculative investment opportunity, given it is potentially undervalued with a "blockbuster-in-waiting" drug candidate so close to approval, and further promising pipeline assets. Read the full article on Seeking AlphaIs Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Nuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish Market
Summary Nuvation Bio's Taletrectinib shows promising data in phase 2 trials for ROS1-positive NSCLC, outperforming current market leaders in key metrics like DOR and PFS. Despite a small target market, Taletrectinib's potential $1bn market opportunity and strong financials make NUVB a compelling investment ahead of its PDUFA. Risks include a competitive landscape with established drugs and emerging rivals like NVL-520, which could impact market share. With solid leadership and a strong cash position, NUVB is well-positioned for growth, making it a stock to watch closely. Read the full article on Seeking AlphaNuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024
Summary Nuvation Bio transitioned from early-stage to late-stage biotech with a near-approval, sitting at a $700 million market cap. The main project is taletrectinib, a novel ROS1 inhibitor with high response rates observed in studies, aiming for NDA filing. Financially stable with cash runway of 12-13 quarters, potential for accelerated approval of taletrectinib, but uncertainty in market adoption. Read the full article on Seeking AlphaIs Nuvation Bio (NYSE:NUVB) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Nuvation Bio: A Potentially Transformative Acquisition
Summary Nuvation Bio stock has been on a roll since late October, as the shares have roughly tripled since then. The main driver of this rally is the potentially transformative acquisition of AnHeart Therapeutics. This greatly enhanced Nuvation's pipeline and prospects. Analyst firms have a universally positive outlook on the company and its equity as well. In addition, Nuvation is well-funded, with the majority of the stock's market cap represented in cash and marketable securities on the company's balance sheet. An analysis around Nuvation Bio follows in the paragraphs below. Read the full article on Seeking AlphaNuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Summary Nuvation Bio has acquired an advanced pipeline candidate, taletrectinib, leading to a surge in market cap approaching $1 billion. Taletrectinib has shown promising clinical activity in treating ROS1-positive non-small cell lung cancer and has Breakthrough Therapy Designation. Nuvation Bio also now has other pipeline candidates, including safusidenib and NUV-868, and has sufficient liquid assets to fund operations for years without help. Read the full article on Seeking AlphaHissedar Getirileri
| NUVB | US Pharmaceuticals | US Pazar | |
|---|---|---|---|
| 7D | 12.0% | 3.4% | -2.1% |
| 1Y | 149.3% | 54.6% | 18.8% |
Getiri vs. Endüstri: NUVB geçen yıl % 54.6 oranında getiri sağlayan US Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: NUVB geçen yıl % 18.8 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| NUVB volatility | |
|---|---|
| NUVB Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: NUVB son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: NUVB 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2018 | 305 | David Hung | www.nuvationbio.com |
Klinik aşamada bir biyofarmasötik şirketi olan Nuvation Bio Inc. kanser tedavisi için ürün adayları geliştirmeye odaklanmaktadır. Şirketin öncü ürün adayı, ROS1+ küçük hücreli dışı akciğer kanseri olan hastaların tedavisi için bir ROS1 inhibitörü olan IBTROZI'dir (taletrectinib). Ayrıca, plaseboya karşı safusidenib ile yüksek riskli veya yüksek dereceli IDH1-mutant astrositomun idame tedavisi için faz 3 klinik çalışmalarda mutant izositrat dehidrojenaz 1 inhibitörü olan Safusidenib'i geliştirmektedir.
Nuvation Bio Inc. Temel Bilgiler Özeti
| NUVB temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$2.55b |
| Kazançlar(TTM) | -US$149.83m |
| Gelir(TTM) | US$169.90m |
NUVB aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| NUVB gelir tablosu (TTM) | |
|---|---|
| Gelir | US$169.90m |
| Gelir Maliyeti | US$20.09m |
| Brüt Kâr | US$149.81m |
| Diğer Giderler | US$299.64m |
| Kazançlar | -US$149.83m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.43 |
| Brüt Marj | 88.18% |
| Net Kâr Marjı | -88.19% |
| Borç/Özkaynak Oranı | 162.5% |
NUVB uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/20 06:26 |
| Gün Sonu Hisse Fiyatı | 2026/08/20 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Nuvation Bio Inc. 15 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Clarence Powell | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |